Gold prices bounce off 3-week lows; demand likely longer term
On Friday, Stifel analysts maintained a Buy rating and a $41.00 price target for Viridian Therapeutics (NASDAQ:VRDN) stock, representing significant upside potential from the current price of $12.65. According to InvestingPro data, analyst targets for VRDN range from $22 to $61, with three analysts recently revising their earnings estimates upward. The firm’s optimism is anchored in the company’s consistent progress in its clinical pipeline and its strategic positioning to become a commercial entity by next year. Stifel’s Alex Thompson highlighted the company’s well-capitalized status, with approximately $720 million in cash as of the fourth quarter of 2024. InvestingPro analysis confirms this strong liquidity position, showing the company holds more cash than debt and maintains a healthy current ratio of 15.43. This robust financial position follows the success of two Phase 3 studies for its leading candidate, Veligrotug, in treating Thyroid Eye Disease (TED).
Viridian’s CEO Steve Mahoney and CBO Shan Wu outlined the company’s roadmap during discussions with Stifel, focusing on Veligrotug’s clinical data and the path to commercialization. The management team is confident in the on-schedule Biologics License Application (BLA) filing for Veligrotug in the second half of 2025, supported by a robust commercial strategy that leverages the product’s unique profile.
The company’s pipeline also includes VRDN-003, a subcutaneous formulation currently in a Phase 3 program, with top-line data expected in the first half of 2026. This development is anticipated to expand Viridian’s growth within the TED market.
In addition, Viridian’s executives underscored the potential of their FcRn franchise, which includes VRDN-006 and VRDN-008. They aim to build upon the success of efgartigimod, a therapy designed for improved treatment options, demonstrating the company’s commitment to innovation and addressing unmet medical needs.
Despite the current negative sentiment surrounding the biotech sector and a challenging six-month period that saw the stock decline by 47%, Viridian Therapeutics appears to be on a solid trajectory towards achieving its commercial and clinical milestones, as reflected in Stifel’s reiterated Buy rating and price target. For deeper insights into VRDN’s valuation and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which includes 14 additional ProTips and detailed financial analysis.
In other recent news, Viridian Therapeutics has announced a new sales agreement with Jefferies LLC, allowing the company to sell up to $300 million worth of common stock through an "at the market" offering. The proceeds from these sales are intended to support the clinical development of Viridian’s product candidates and prepare for potential commercialization. This new agreement replaces a previous arrangement with Jefferies that allowed for the sale of up to $175 million in common stock. In another development, Stifel analysts have maintained their Buy rating on Viridian shares, highlighting the promising outcomes from Phase 3 studies for Veligrotug, a treatment for Thyroid Eye Disease. The analysts emphasize the potential market success of Viridian’s subcutaneous drug, VRDN-003, due to its favorable dosing schedule. Additionally, Viridian has made changes to its Board of Directors with the appointment of Christopher Cain, Ph.D., as a Class I director, coinciding with the resignation of Peter Harwin. These recent developments indicate significant strategic and operational moves by Viridian Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.